6472 Stock Overview
Researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Bora Pharmaceuticals Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$780.00 |
| 52 Week High | NT$975.00 |
| 52 Week Low | NT$612.00 |
| Beta | 0.69 |
| 11 Month Change | 5.55% |
| 3 Month Change | 1.56% |
| 1 Year Change | 20.74% |
| 33 Year Change | 457.45% |
| 5 Year Change | 1,018.66% |
| Change since IPO | 1,634.41% |
Recent News & Updates
Recent updates
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Nov 21
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
Oct 04Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Jul 18Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Jun 13Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?
Apr 30Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?
Mar 17Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment
Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)
Jan 27Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt
Jan 19We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings
Dec 29Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?
Dec 09Shareholder Returns
| 6472 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.6% | 0.6% | -0.8% |
| 1Y | 20.7% | 9.2% | 29.0% |
Return vs Industry: 6472 exceeded the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 6472 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 6472 volatility | |
|---|---|
| 6472 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6472 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6472's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Bobby Sheng | www.bora-corp.com |
Bora Pharmaceuticals Co., LTD. researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. The company operates through Sales, Contract Development & Manufacturing Organization, and Other segments.
Bora Pharmaceuticals Co., LTD. Fundamentals Summary
| 6472 fundamental statistics | |
|---|---|
| Market cap | NT$81.52b |
| Earnings (TTM) | NT$3.90b |
| Revenue (TTM) | NT$16.71b |
20.6x
P/E Ratio4.8x
P/S RatioIs 6472 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6472 income statement (TTM) | |
|---|---|
| Revenue | NT$16.71b |
| Cost of Revenue | NT$9.18b |
| Gross Profit | NT$7.53b |
| Other Expenses | NT$3.63b |
| Earnings | NT$3.90b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.94 |
| Gross Margin | 45.08% |
| Net Profit Margin | 23.35% |
| Debt/Equity Ratio | 128.3% |
How did 6472 perform over the long term?
See historical performance and comparison